A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Prostate Cancer

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Prostate Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs CV 9104 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors CureVac
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 11 Feb 2017 This trial has been discontinued in Spain.(End date:2017-01-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top